Mafosfamida (BioDeep_00000650706)

   


代谢物信息卡片


Mafosfamida

化学式: C9H19Cl2N2O5PS2 (399.98500340000004)
中文名称: 马磷酰胺
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1COP(=O)(NC1SCCS(=O)(=O)O)N(CCCl)CCCl
InChI: InChI=1S/C9H19Cl2N2O5PS2/c10-2-4-13(5-3-11)19(14)12-9(1-6-18-19)20-7-8-21(15,16)17/h9H,1-8H2,(H,12,14)(H,15,16,17)

描述信息

D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D009588 - Nitrogen Mustard Compounds
D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D010752 - Phosphoramide Mustards
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
D007155 - Immunologic Factors

同义名列表

2 个代谢物同义名

Mafosfamida; Mafosfamide



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • P S Schwartz, D J Waxman. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Molecular pharmacology. 2001 Dec; 60(6):1268-79. doi: 10.1124/mol.60.6.1268. [PMID: 11723234]
  • D E Reece, D A Brockington, G L Phillips, M J Barnett, H G Klingemann, S H Nantel, H J Sutherland, J D Shepherd. Prolonged survival after intensive therapy and purged ABMT in patients with multiple myeloma. Bone marrow transplantation. 2000 Sep; 26(6):621-6. doi: 10.1038/sj.bmt.1702574. [PMID: 11041567]
  • P Schlenke, J Kisro, M Deeken, S Zajac, S Klich, T Wagner. The cytotoxicity of mafosfamide on G-CSF mobilized hematopoietic progenitors is reduced by SH groups of albumin--implications for further purging strategies. Bone marrow transplantation. 1999 Jan; 23(2):157-61. doi: 10.1038/sj.bmt.1701541. [PMID: 10197801]
  • K W Wolf, M Mentzel, A S Mendoza. Treatment with the anti-tumor drugs, cis-platin and mafosfamide, does not affect the structure of prekinetochores in a human breast cancer cell line. An immunofluorescence study using human anti-centromere autoantibodies. Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft. 1996 Oct; 178(5):425-32. doi: 10.1016/s0940-9602(96)80132-4. [PMID: 8931853]
  • M C Giarratana, N C Gorin, L Douay. Plasma interacts with mafosfamide toxicity to normal haematopoietic progenitor cells: impact on in vitro marrow purging. Nouvelle revue francaise d'hematologie. 1995; 37(2):125-30. doi: NULL. [PMID: 7644349]
  • P A te Boekhorst, B Löwenberg, M Vlastuin, P Sonneveld. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia. 1993 Aug; 7(8):1191-8. doi: NULL. [PMID: 7688839]
  • L Sreerama, N E Sladek. Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Biochemical pharmacology. 1993 Jun; 45(12):2487-505. doi: 10.1016/0006-2952(93)90231-k. [PMID: 8328987]
  • B Jansen, J H Kersey, W B Jaszcz, R Gunther, D P Nguyen, L M Chelstrom, L Tuel-Ahlgren, F M Uckun. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide. Leukemia. 1993 Feb; 7(2):290-7. doi: ". [PMID: 7678881]
  • A Schomburg, T Menzel, M Hadam, S Duensing, A Körfer, H Kirchner, H Poliwoda, J Atzpodien. Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma. Molecular biotherapy. 1992 Jun; 4(2):58-65. doi: NULL. [PMID: 1515095]
  • O G Ottmann, C C Stella, M Eder, P Reutzel, S Ströcker, D Hoelzer, A Ganser. Regulation of early hematopoiesis in serum-deprived cultures of mafosfamide-treated and untreated CD34-enriched bone marrow cells. Experimental hematology. 1991 Sep; 19(8):773-8. doi: NULL. [PMID: 1714403]
  • H Futami, R Jansen, M J MacPhee, J Keller, K McCormick, D L Longo, J J Oppenheim, F W Ruscetti, R H Wiltrout. Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy. Journal of immunology (Baltimore, Md. : 1950). 1990 Dec; 145(12):4121-30. doi: NULL. [PMID: 2258610]
  • R Pieters, A H Loonen, D R Huismans, G J Broekema, M W Dirven, M W Heyenbrok, K Hählen, A J Veerman. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood. 1990 Dec; 76(11):2327-36. doi: . [PMID: 2257305]
  • H Blomgren, M Hallström. Possible role of acrolein in oxazaphosphorine-induced enhancement of immunological reactivity. Cancer immunology, immunotherapy : CII. 1990; 31(4):221-5. doi: 10.1007/bf01789172. [PMID: 2143101]
  • J Limpens, J Garssen, R J Scheper. Local administration of cytostatic drugs enhances delayed-type hypersensitivity to Sendai virus in mice. Clinical immunology and immunopathology. 1990 Jan; 54(1):161-5. doi: 10.1016/0090-1229(90)90015-i. [PMID: 2152858]
  • J Limpens, R J Scheper. Synergistic effects of locally administered cytostatic drugs and a surfactant on the development of delayed-type hypersensitivity to keyhole limpet haemocyanin in mice. Clinical and experimental immunology. 1989 Nov; 78(2):256-62. doi: ". [PMID: 12412759]
  • C H Kwon, R F Borch, J Engel, U Niemeyer. Activation mechanisms of mafosfamide and the role of thiols in cyclophosphamide metabolism. Journal of medicinal chemistry. 1987 Feb; 30(2):395-9. doi: 10.1021/jm00385a023. [PMID: 3806619]